Tagged with innovation,

Europe Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and…

Taiwan Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its evolving focus beyond neuroscience. She discusses the region’s innovation potential, the strategic priorities driving rare disease and other exciting therapeutic…

Hong Kong Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute (GBAICTI), and leveraging 34 years of real-world health data. She underscores efforts to enhance primary healthcare, support rare disease access,…

USA As rare disease science accelerates, regulators face growing pressure to adapt without compromising rigour. In this interview, Amy Comstock Rick explains how the FDA Rare Disease Innovation Hub is strengthening cross-centre coordination, evolving evidence expectations for ultra-rare conditions, and creating new spaces for dialogue between regulators, developers, and patients. The…

Taiwan Epidemiologist Dr Chen Chien-jen has spent decades at the intersection of scientific research and public health policy. His pioneering work on arsenic-induced health hazards informed international water safety standards, whilst his leadership during the SARS outbreak established Taiwan’s pandemic preparedness infrastructure. In this wide-ranging conversation, Dr Chen discusses Taiwan’s approach…

Taiwan Taiwan is entering a pivotal phase in its healthcare evolution, and Roche’s leaders in Taiwan outline how the convergence of global expertise, advanced diagnostics and innovative therapeutics can accelerate that shift. Diana Liu and Sophia Chao describe an ecosystem that is eager to adopt prevention, early detection and personalised care,…

Hong Kong Amy Ho, General Manager of Roche Pharma Hong Kong, returns to the city with a unique blend of diagnostics and pharmaceutical experience at a moment when the healthcare system is redefining its future. Drawing on years of regional leadership, she offers a clear view of how Hong Kong can strengthen…

France Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With two years at LEEM and one year on the EFPIA Board, Peyraut is operating under unprecedented geopolitical pressures reshaping pharmaceutical…

France Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on the scientific foundations of RNAi, the strengths and pressures of the French rare-disease ecosystem, and the conditions needed to ensure…

Taiwan Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep understanding of cross-cultural business dynamics and healthcare system transformation. Since assuming his current role, he has spearheaded an ambitious organisational…

Brazil Brazil’s push to modernise its health system has put Interfarma at the centre of the region’s biggest access debate. Since taking over the presidency in 2023, Renato Porto has steered the association – which represents the innovative pharmaceutical industry in Brazil – through a period of regulatory reform, political uncertainty,…

LatAm Alexandre Gibim, senior Vice President of Latin America at AstraZeneca, brings extensive global pharmaceutical leadership experience spanning China, the US, and Canada. In this exclusive interview, he articulates AstraZeneca’s strategic commitment to Latin America as a critical growth engine, detailing the company’s 110 million USD (two billion Mexican peso) investment…